Breast Cancer Index regulatory update

BioMerieux's Biotheranostics Inc. company said CMS posted a positive coverage and reimbursement policy for the Breast Cancer Index to determine the risk of early and late recurrence and benefit from extended endocrine therapy in patients with early stage, estrogen receptor-positive breast cancer. The policy covers use of the test to predict late (5-10 years) distant recurrence in women who are considering extended therapy but are concerned about continuing anti-hormonal therapy because of documented toxicity or possible significant patient-specific side effects. Medicare coverage and payment for the assay will be made for new claims and retrospectively for previously submitted claims. ...